daunorubicin has been researched along with Myasthenia Gravis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Llorente, L; Richaud-Patin, Y; Vega-Boada, F; Vidaller, A | 1 |
| Christadoss, P; Henderson, R; Keve, S | 1 |
| Fujii, Y; Knogge, W; Lindstrom, J; Shelton, D | 1 |
1 trial(s) available for daunorubicin and Myasthenia Gravis
| Article | Year |
|---|---|
Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azathioprine; Daunorubicin; Female; Flow Cytometry; Fluorescent Dyes; Glucocorticoids; Humans; Immunosuppressive Agents; Lymphocytes; Male; Middle Aged; Myasthenia Gravis; Prednisolone | 2004 |
2 other study(ies) available for daunorubicin and Myasthenia Gravis
| Article | Year |
|---|---|
Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Body Weight; Daunorubicin; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Myasthenia Gravis; Organ Size; Receptors, Cholinergic | 1991 |
Specific suppression of the antibody response to acetylcholine receptor in vitro and in vivo by daunomycin-acetylcholine receptor conjugates.
Topics: Animals; Antibody Formation; Daunorubicin; Immunotherapy; Myasthenia Gravis; Rats; Receptors, Nicotinic | 1988 |